Cargando…
Microdystrophin Gene Addition Significantly Improves Muscle Functionality and Diaphragm Muscle Histopathology in a Fibrotic Mouse Model of Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a rare neuromuscular disease affecting 1:5000 newborn males. No cure is currently available, but gene addition therapy, based on the adeno-associated viral (AAV) vector-mediated delivery of microdystrophin transgenes, is currently being tested in clinical trials....
Autores principales: | Cernisova, Viktorija, Lu-Nguyen, Ngoc, Trundle, Jessica, Herath, Shan, Malerba, Alberto, Popplewell, Linda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179398/ https://www.ncbi.nlm.nih.gov/pubmed/37175881 http://dx.doi.org/10.3390/ijms24098174 |
Ejemplares similares
-
Microdystrophin Expression as a Surrogate Endpoint for Duchenne Muscular Dystrophy Clinical Trials
por: Chamberlain, Jeffrey S., et al.
Publicado: (2023) -
Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
por: Le Guiner, Caroline, et al.
Publicado: (2017) -
Differential Effects of Halofuginone Enantiomers on Muscle Fibrosis and Histopathology in Duchenne Muscular Dystrophy
por: Mordechay, Sharon, et al.
Publicado: (2021) -
Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD)
por: Harish, Pradeep, et al.
Publicado: (2019) -
Transplantation of human iPSC-derived muscle stem cells in the diaphragm of Duchenne muscular dystrophy model mice
por: Miura, Yasutomo, et al.
Publicado: (2022)